ClinicalTrials.gg
CompletedNCT06453954eVOLVEUpdated Jun 12, 2024

Evaluating the Saving Babies Lives Care Bundle Version 2

An observational study in Pregnancy Related and Delivery of Health Care, sponsored by University of Manchester. Completed at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by University of Manchester · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,773
Ages
16 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn about the implementation of NHS England's Saving Babies Lives Care Bundle Version 2 to reduce perinatal mortality.

It will explore whether the care bundle is effective at reducing stillbirth rates, neonatal death rates and preterm births in England. It will also explore the lived experiences of women's maternity care and their babies neonatal care, and the views and experiences of healthcare professionals who are involved in delivering the care bundle.

The main questions it aims to answer are:

  • Does the care bundle reduce perinatal mortality rates?
  • What are women's views and experiences of their maternity and neonatal care?
  • What are the barriers around delivering the care bundle and how can this be improved?
  • How do health inequalities affect the care women receive?
  • How does the workforce culture affect how healthcare professionals use the care bundle?

Perinatal mortality rates and other pregnancy outcomes will be obtained from national data sources. Women and healthcare professionals will be asked to complete a survey and we will interview select groups of participants to further explore their experiences.

Mortality rates will be compared before and after the implementationof the care bundle where data allows. Data from the surveys will be descriptive. Data from the interviews will be analysed using thematic analysis to determine patterns and recurring ideas in the data.

Read the detailed description

In April 2022, NHS England commissioned the University of Manchester to conduct an independent evaluation of the effectiveness of the Saving Babies' Lives Care Bundle Version 2 (SBLCBv2) on reducing perinatal mortality in England. The study was commissioned in two phases.

Phase 1 comprises a national (service) evaluation of the impact of the SBLCBv2 on perinatal mortality rates, associated clinical outcomes, and any unintended consequences using routine data derived from national databases. Phase 2 comprises a qualitative evaluation to further understand the impact on maternity services, women and their families.

Phase 2 will be conducted in a cohort of maternity units across England using a mixed-methods approach. The views and experiences of women and healthcare professionals towards maternity care in relation to the SBLCBv2 will be sought using surveys and interviews. Additionally, this study will interview organisational leads to assess how resources, leadership and governance may affect implementation in diverse hospital settings.

02

Conditions studied

  • Pregnancy Related
  • Delivery of Health Care

Keywords

  • Saving Babies Lives Care Bundle Version 2
  • NHS Maternity Care
  • Pregnancy
  • Stillbirth
  • Perinatal death
03

In context

Stillbirth

121 studies on the registry are indexed under Stillbirth; 34 are open to participants now.

This study's enrollment of 1,773 is above the median of 794 across 52 observational studies indexed under Stillbirth.

Browse Stillbirth studies →

Lead sponsor

University of Manchester is the lead sponsor of 201 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Phase 1: births in England.

Phase 2: women who received their antenatal care, labour and birth in 28 participating NHS maternity Trusts in England. Healthcare professionals currently employed in these 28 Trusts.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Phase 1:

All births in England.

Phase 2:

Inclusion criteria

Inclusion Criteria:

  • women who have given birth in the last 12 months
  • women who can understand English
  • healthcare professionals involved in delivering the care bundle

Exclusion criteria

Exclusion Criteria:

  • women who gave birth more than 12 months ago
  • women who cannot understand English
  • women without access to the internet for online survey completion
  • healthcare professionals not involved in delivering the care bundle
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,773 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of stillbirths in England

    A baby born after 24 or more weeks completed gestation and which did not, at any time, breathe or show signs of life

    Time frame: Up to 60 months

Secondary outcomes

  1. Number of babies born preterm

    A baby born before 37 weeks gestation

    Time frame: Up to 60 months

  2. Number of neonatal deaths in England

    A live born baby (born at 20+0 weeks gestational age or later, or with a birthweight of 400g or more where an accurate estimate of gestation is not available), who died before 28 completed days after birth

    Time frame: Up to 60 months

  3. Number of babies born small for gestational age (SGA)

    Birthweight less than the 10th percentile for gestational age

    Time frame: Up to 60 months

  4. Number of women who had a caesarean section

    Women delivering by emergency or elective caesarean section

    Time frame: Up to 60 months

  5. Number of women who had induction of labour

    Induced delivieries

    Time frame: Up to 60 months

  6. Number of women who had an instrumental delivery

    Women who had a forceps or ventouse delivery

    Time frame: Up to 60 months

  7. Number of women who had a spontaneous delivery

    Spontaneous delivery without forceps or ventouse delivery

    Time frame: Up to 60 months

  8. Number of babies admitted to neonatal care

    A baby first admitted at the given quarter to any neonatal care unit

    Time frame: Up to 84 months

  9. Number of babies admitted to neonatal care by gestation

    A baby first admitted at the given quarter to a neonatal care unit by gestation weeks at birth

    Time frame: Up to 84 months

  10. Number of babies admitted to neonatal care by cause of death

    A baby first admitted at the given quarter to a neonatal care unit by clinical diagnosis

    Time frame: Up to 84 months

  11. Number of babies who died whilst on neonatal care

    A baby first admitted at any given quarter to a neonatal care unit that died at any point

    Time frame: Up to 84 months

07

Study locations

1 site
  • Manchester Foundation Trust
    Manchester, M13 9WL, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — If requested, site-specific data from the questionnaires may be shared with participating NHS Trusts. This data will be provided in an anonymous aggregated format, with only that specific site identified. No identifiable data will be shared with participating NHS Trusts (i.e. names and email addresses will not be shared with NHS sites). Following completion of the study, with consent a fully anonymised aggregated dataset [e.g. including anonymous aggregated questionnaire responses] will be deposited in Figshare at the University of Manchester library, which is an open data repository where it will be permanently stored. Researchers at other institutions and others can access the anonymised data directly from the repository and use it for further research or to check our analysis and results. Individual NHS Trusts will not be identified.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jan 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
Jun 12, 2024
StartActual
Oct 17, 2023
Primary completionActual
Jan 31, 2024
CompletionActual
Feb 21, 2024
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06453954
Responsible party
Dr Alexander Heazell (Professor of Obstetrics, University of Manchester) — Principal investigator
First posted
Jun 12, 2024
Start date
Oct 17, 2023
Primary completion
Jan 31, 2024
Completion
Feb 21, 2024
Last update
Jun 12, 2024

Study contacts

Alexander Heazell, Prof
principal investigator · The University of Manchester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion